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Vaccines to prevent Trypanosoma cruzi infection in humans or animals are not available, and in many settings, dogs
are an important source of domestic infection for the insect vector. Identification of infected canines is crucial for
evaluating peridomestic transmission dynamics and parasite control strategies. As immune control of T. cruzi
infection is dependent on humoral and cell-mediated immune responses, we aimed to define a serodiagnostic
assay and T cell phenotypic markers for identifying infected dogs and studying the canine T. cruzi-specific immune
response. Plasma samples and peripheral blood mononuclear cells (PBMCs) were obtained from forty-two dogs
living in a T. cruzi-endemic region. Twenty dogs were known to be seropositive and nine seronegative by
conventional serologic tests two years prior to our study. To determine canine seroreactivity, we tested sera or
plasma samples in a multiplex bead array against eleven recombinant T. cruzi proteins. Ninety-four percent (17/18)
of dogs positive by multiplex serology were initially positive by conventional serology. The frequency of
IFNγ-producing cells in PBMCs responding to T. cruzi correlated to serological status, identifying 95% of multiplex
seropositive dogs. Intracellular staining identified CD4+ and CD8+ T cell populations as the sources of T. cruzi
lysate-induced IFNγ. Low expression of CCR7 and CD62L on CD4+ and CD8+ T cells suggested a predominance of
effector/effector memory T cells in seropositive canines. These results are the first, to our knowledge, to correlate
T. cruzi-specific antibody responses with T cell responses in naturally infected dogs and validate these methods for
identifying dogs exposed to T. cruzi.Introduction
Trypanosoma cruzi infects humans, wildlife, and domestic
animals throughout the Americas. Worldwide, it is esti-
mated that at least ten million individuals are chronically
infected with T. cruzi, with twenty-five million more are
at risk of infection [1]. T. cruzi infection predominantly
burdens countries of Central and South America but
encompasses all of the Americas including the United
States, contributing 14 000 deaths annually and 700 000
daily adjusted life years [2]. Current methods of parasite
control, diagnostics, and treatment are inadequate in
completely disrupting transmission as new infections
occur annually, and no vaccines are currently available
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reproduction in any medium, provided the orDogs play a significant role in T. cruzi epidemiology
and ecology as reservoirs for infection [3]. Preferential
[4] and host tolerant [5] vectorial feeding of dogs, higher
T. cruzi infectivity of Triatoma infestans upon feeding
on dogs compared to human feeding [6], and the close
proximity of dogs to humans in domiciles in T. cruzi
endemic regions [7] identifies dogs as a critical control
point for T. cruzi transmission. Strategies for interrupting
transmission by targeting the dog have included insecticide-
impregnated dog collars [8] and various means of vaccin-
ation [9-11]. Despite these efforts, peridomestic T. cruzi
transmission still occurs between humans, dogs, and
the insect vector [3]. Identifying infected canines and
understanding the immune mechanisms responsible for
canine T. cruzi recognition and control are critical for
designing and evaluating future intervention strategies
targeting canines.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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T. cruzi infection are not considered to be definitive,
positive responses on a minimum of two tests is generally
recommended to identify infected humans [12-14], and
dogs [15,16]. For identifying circulating anti-T. cruzi anti-
bodies, hemagglutination, complement fixation, indirect
immunofluorescence, and direct agglutination tests have
been standardized for canine sera [17]. These methods,
also known broadly as conventional serological assays,
predominantly utilize insect stage epimastigote-derived
antigens for seroreactivity testing. In an attempt to im-
prove the quality of serological tests for detection of
T. cruzi infection, we developed a multiplex bead array
format utilizing recombinant T. cruzi proteins selected for
their predicted expression during mammalian infection
stages [18], high abundance in trypomastigote and amasti-
gote proteomes [19], and ability to detect the broad array
of responses observed in T. cruzi-infected humans [20].
Investigating serological assays employing mammalian-
stage derived proteins could maximize discrimination of
seropositive and seronegative canines, thereby reducing
the need for multiple tests to identify seroreactive dogs
during intervention campaigns.
Studies of human T. cruzi infection and experimental
animal models have highlighted the role antibodies
[21-23], CD4+ and CD8+ T cells [24-26], and effector
cytokines [27,28] serve in immune control of T. cruzi,
predicting disease development, and determining treat-
ment success. Identification of T. cruzi-specific CD8+ T
cells by class I MHC tetramers for mice [29] and humans
[27] has facilitated monitoring of cell surface marker
expression and effector function of T. cruzi-specific T
cells. In particular, correlation of parasitological cure with
increased CD127 and CD62L expression by T. cruzi-
specific CD8+ T cells in benznidazole-treated mice has
identified biomarkers for evaluating parasite burden
in vivo [30]. Characterizing similar canine T cell phenotypes
and effector cytokine production is critical for understand-
ing the development of an appropriate T. cruzi-specific
immune response in the dog and evaluating modulation
of this response following intervention strategies targeting
the dog.
The aim of this study was to test the use of a multiplex
serodiagnostic assay for T. cruzi in dog sera or plasma
and to further evaluate T cell phenotypes and effector
cytokine production associated with canine T. cruzi infec-
tion. Peripheral blood was collected from dogs previously
tested by conventional serology and/or xenodiagnosis and
living in a T. cruzi-endemic region of northern Argentina.
Plasma were submitted to multiplex bead array analysis
using eleven recombinant T. cruzi proteins, previously
described for identifying seroreactive humans and evaluat-
ing treatment success [20], and PBMCs were assessed for
IFNγ production in response to T. cruzi amastigoteantigens by ELISpot. Utilizing recently identified T cell
reagents identified for the dog (Hartley and Tarleton,
unpublished), we assessed expression of canine T cell
surface markers associated with naïve or central mem-
ory and activated T cells. The results of this study deter-
mined dogs living in T. cruzi-endemic regions develop
robust anti-T. cruzi antibody responses which correlate
with T cell effector and activation phenotypes. The sero-
logical and T cells assays described here provide a plat-
form for monitoring canine immune responses and for




A maximum of 10 mL of blood from 42 dogs living in
four villages in Pampa del Indio, Chaco, Argentina were
drawn into heparinized tubes (BD Vacutainer, BD, Franklin
Lakes, NJ, USA) by venipuncture. A proportion of these
dogs had been previously screened and found to be
seropositive or seronegative for T. cruzi by conventional
serology (see below). Approximately 50 mL of blood from
three clinically healthy dogs and sera from 5 additional
healthy dogs from the United States were obtained to serve
as controls. Isolation of peripheral blood mononuclear
cells (PBMCs) occurred within 24 h of collection. Briefly,
PBMCs were isolated by density gradient centrifugation
on Lymphocyte Separation Medium (MP Biomedicals,
Solon, OH, USA), resuspended in complete RPMI 1640
supplemented with 10% heat-inactivated FCS (HyClone
Laboratories, ThermoScientific, Logan, UT, USA), and
stored frozen at -80 °C. These purification, storage, and
recovery procedures yielded > 80% viability for Argentinean
and > 95% viability for North American dogs as deter-
mined by microscopic examination of trypan blue ex-
clusion. Plasma samples were collected during PBMC
isolation and stored frozen at -20 °C. Informed oral con-
sent was requested and obtained from each head of
household for samples collected in Argentina. Animal
use protocols for samples collected in the United States
were approved by the University of Georgia Institutional
Animal Care and Use Committee. Blood collection in
Argentina was conducted according to the protocol ap-
proved by the Argentinean “Dr Carlos Barclay” Independent
Ethical Committee for Clinical Research (IRB No. 00001678,
NIH registered, and Protocol No. TW-01-004).
Initial conventional serology and xenodiagnosis
Indirect hemagluttination assay (IHA) and an in-house
enzyme-linked immunosorbent assay (ELISA) modified
from a standardized protocol [15] were used to test sera
for anti-T. cruzi antibodies two years prior to collection
of PBMC and plasma for this study [31]. Sera were con-
sidered discordant if results of IHA and ELISA reactivity
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xenodiagnosis, as previously outlined [31] and notated in
Table 1. Briefly, boxes containing uninfected fourth-instar
nymphs of T. infestans were exposed to the abdomen of
an individual dog. Insect feces were examined microscop-
ically at 30 and 60 days later for T. cruzi infection.
T. cruzi amastigote lysate
Brazil strain trypomastigotes were cultured overnight
in pH 5 RPMI 1640 supplemented with 10% FCS and
10 mM phosphate citrate buffer to transform trypomasti-
gotes into amastigotes. After two PBS washes, parasites
were frozen at -20 °C. Frozen aliquots were subjected to
five freeze/thaw cycles followed by three 10s sonications
in a FS15 sonicator (Fisher Scientific, Pittsburgh, PA,
USA). The supernatant of a 12 000 rpm centrifugation
was collected, filter sterilized, and protein concentration
determined by Bradford assay.
Serology testing with protein multiplex bioassay
Canine plasma samples were tested with a recombinant
T. cruzi protein multiplex assay previously described in
detail for testing T. cruzi reactivity of human sera samples
[20]. Briefly, sera or plasma are diluted 1:500 and incu-
bated with a pool of 11 recombinant proteins attached to
addressable Liquichip Ni-NTA beads (Qiagen Inc, Valen-
cia, CA, USA) and T. cruzi amastigote lysate coupled to
Carboxy-Ni-NTA beads (Qiagen Inc). Following washing,
antibody binding was detected with goat anti-dog IgG
conjugated to phycoerythrin (Santa Cruz Biotechnology
Inc, Santa Cruz, CA, USA) and quantified on a Bio-Plex
Suspension Array System (Bio-Rad, Hercules, CA, USA).
Serum samples were assayed in duplicate and weighted
mean fluorescence intensity (MFI) was calculated. The ra-
tio of the specific MFI for each antigen versus a negative
control (green fluorescent protein) protein was calculated
for each antigen and sera or plasma in the assay.
IFNγ ELISpot assays
Four hundred thousand PBMCs were cultured in media,
2 ng/mL phorbol 12-myristate 13-acetate (PMA) and
500 ng/mL Ca2+ ionomycin (both Sigma-Aldrich, St.
Louis, MO, USA), or 10 μg/mLT. cruzi amastigote lysate
for 16 h at 37 °C and 5% CO2. Cells were assayed for IFNγ
production using the Canine IFN-γ ELISpot kit (cat no.
EL781, R& D Systems, Inc, Minneapolis, MN, USA) fol-
lowing standard kit protocol. Enumeration of spot forming
cells was completed by an ImmunoSpot analyzer (CTL,
Cleveland, OH, USA). Mean numbers of spots from dupli-
cate or triplicate well were obtained for media and T. cruzi
lysate stimulation conditions. Responses were considered
positive if a minimum of 20 spots/106 PBMC total were
present and this number was at least twice the value of
wells assayed with media alone [27].Intracellular cytokine staining
For assaying IFNγ production, 4 × 105 PBMCs were stimu-
lated for 5 h in the presence of 2 ng/mL PMA, 4 μg/mL
Ca2+ ionomycin (Sigma-Aldrich), and brefeldin A (BD
GolgiPlug; BD Biosciences, San Jose, CA, USA) adapted
from described stimulation conditions [32] or overnight
with 40 μg/mLT. cruzi lysate at 37 °C. Brefeldin A was
added 5 h prior to end of incubation, and the cells were
stained with anti-CD8-Pacific Blue and anti-CD4-FITC
(AbD Serotec, Raleigh, NC, USA) followed by intracellular
staining with anti-bovine IFN-γ AF647 (AbD Serotec) ac-
cording to the BD Cytofix/Cytoperm kit (BD Biosciences).
Samples were fixed in 2% formaldehyde prior to analysis
by flow cytometry.
CTL2.58 purification and PE-Cy7 labeling
Culture supernatants containing clone CTL2.58 IgG were
a kind gift of Dr Mary Tompkins, North Carolina State
University, Raleigh, NC. Immunoglobulins were purified
according to instructions of the Pierce Thiophilic Adsorp-
tion Kit (cat no 44916, Thermo Scientific, Rockford, IL,
USA). Elutions containing targeted heavy and light chain
were confirmed by SDS-PAGE and conjugated to PE-Cy7
using Lightning-Link PE-Cy7 antibody labeling kit (cat
no 762-0015, Novus Biologicals, Littleton, CO, USA)
following manufacture instructions. ConA-stimulated
canine PBMCs were used for positive reactivity for
CTL2.58-Pe-Cy7 staining (Additional file 1).
Cell surface phenotyping
PBMCs (500 000) were incubated in complete RPMI 1640
supplemented with 10% heat-inactivated FCS for 1 h at
37 °C, centrifuged, and resuspended in 100 μL of CCL19-
hIg (ELC; [33]) culture supernatant for 45 min at 4 °C.
After incubation, cells were washed and resuspended
for staining in PAB solution containing PBS with 1%
BSA and 0.05% sodium azide (both from Sigma-Aldrich).
Antibodies used were anti-CD8 PacBlue, anti-CD4 AF647,
anti-CD62L PE (AbD Serotec), CTL2.58-PeCy7, and anti-
human IgG AF488 (Molecular Probes, Eugene, OR, USA).
7-amino-actinomycin D (7AAD, BD Pharmingen, BD
Biosciences, San Jose, CA, USA) was included for live/
dead cell discrimination. Following incubation of PBMCs
with antibody mixes for 45 min on ice, cells were washed
twice, fixed in 2% formaldehyde, and analyzed by flow
cytometry.
Flow cytometry and statistical analysis
Fixed PBMC samples were collected on a CyAn ADP
using Summit, version 4.3 (Beckman Coulter, Fullerton,
CA, USA). FlowJo flow cytometry analysis software, version
8 (Tree Star, Ashland, OR, USA) was used for analyses.
Positive gates were determined by relevant fluorescence
Table 1 Comparison of xenodiagnosis, initial conventional serology,
multiplex serology, and IFNγ ELISpot assays







160 - - 0 0
163 - - 0 0
280 - - 0 0
281 - - 0 0
283 - - 0 3
187 n.d. - 0 0
258 n.d. - 0 0
259 n.d. - 0 0
267 n.d. - 0 0
198 n.d. + 0 0
200 n.d. + 0 0
588 n.d. discordant 1 0
260 n.d. n.d. 0 0
B n.d. n.d. 0 0
D n.d. n.d. 0 0
F n.d. n.d. 0 0
I n.d. n.d. 0 n.d.
J n.d. n.d. 0 0
K n.d. n.d. 0 3
L n.d. n.d. 0 0
M n.d. n.d. 0 0
0/21 0/20
Responders
152 - + 6 400
71 + + 5 55
154 + + 3 108
157 + + 5 13 (-)
159 + + 3 290
266 + n.d. 3 55
272 + + 2 50
274 + + 2 68
276 + + 4 363
284 + + 3 955
43 n.d. + 4 233
67 n.d. + 1 80
69 n.d. + 5 550
193 n.d. + 4 130
197 n.d. + 2 63
434 n.d. + 5 58
572 n.d. + 4 n.d.
573 n.d. + 3 398
589 n.d. + 4 33
P n.d. n.d. 3 823
O n.d. n.d. 5 520
20/21 19/20
Controls (US)
1 n.d. n.d. 0 0
2 n.d. n.d. 0 3
3 n.d. n.d. 0 0
4 n.d. n.d. 0 n.d.
5 n.d. n.d. 0 n.d.
6 n.d. n.d. 0 n.d.
7 n.d. n.d. 0 n.d.
8 n.d. n.d. 0 n.d.
0/8 0/3
Forty-two samples from dogs living in a T. cruzi-endemic region are grouped as non-
responders and responders based on reactivity to T. cruzi lysate in serological and effector
function assays. Test reactivity is annotated as positive (+), negative (-), discordant (disc), or
not determined (n.d.). Controls are canine samples from dogs living in the United States.
Bold data are results presented as # positive individuals/# total individuals of the groups.
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using Prism v4.0c (GraphPad Software, La Jolla, CA, USA).
Results
Our first aim was to test an improved serodiagnostic assay
for the ability to detect T. cruzi infection in canines. Sera
and plasma samples were obtained from eight healthy
dogs from the United States (US) and forty-two dogs liv-
ing in a T. cruzi-endemic region of northern Argentina.
Twenty Argentinean dogs were known to be seropositive,
nine seronegative, and one discordant by conventional ser-
ology two years prior to this study. Ten dogs were new ad-
ditions to domiciles and had not been previously tested.
We employed a multiplex bead array format previously
utilized for identifying and discriminating humans reactive
to recombinant T. cruzi proteins, in which proteins were
selected for their predicted expression during mammalian
infection stages and high abundance in the trypomastigote
and amastigote T. cruzi proteome [20]. Addressable beads
were bound to eleven recombinant T. cruzi proteins, incu-
bated with sera or plasma, followed with a secondary fluor-
ophore conjugated anti-canine specific IgG, and quantified
on a BioPlex Suspension Array System (BioRad) for mean
fluorescence intensity (MFI). We first tested a subset of
dogs and found that as expected, animals positive by con-
ventional serology had considerably higher MFI values than
United States control dogs or seronegative Argentinean
dogs (Figure 1). All proteins in the multiplex assay
showed reactivity with serum from at least one dog with
a subset of six recombinant proteins (60S acidic ribosomal
subunit protein, microtubule-associated protein homo-
log, glycosomal phosphoenolpyruvate carboxylase, fla-
gellar calcium binding protein, major paraflagellar rod
protein, and a hypothetical protein) identifying all initial
conventional serology positive canines. All conventional
serology positive dogs showed reactivity above a MFI of
10 000 to at least one protein or greater than 6500 MFI
for at least four proteins in the multiplex array. One
discordant dog, dog 588, had no significant responses to
the subset of six recombinant proteins identifying all
conventional serology positive canines. However dog 588
did have greater than 10 000 MFI to calmodulin protein-
coated beads, but this reactivity was not observed in any
other dog. These results validate a multiplex serological
assay platform for identifying circulating anti-T. cruzi
antibodies in the dog using mammalian-stage derived
T. cruzi-recombinant proteins.
We next tested all Argentinean canine plasma samples
creating a metric of reactivity by calculating the standard
deviation of each individual plasma sample for each indi-
vidual protein over reactivity to all conventional serology
negative animals. Using a minimum reactivity to two
proteins with four standard deviations above that of the
seronegative individuals, ninety-four percent (17/18) of
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positive with conventional serology (Table 1). Two con-
ventional serology positive dogs (dogs 198 and 200) had
no significant responses to any recombinant proteins in
the multiplex assay. All nine initial seronegative dogs were
also negative in the multiplex bead serological assay.
Analysis of eleven dogs without previous conventional
serology revealed two additional seropositive animals, dog
O and P.
Measurement of T. cruzi-specific T cells has proven
useful for confirming and monitoring infection status in
humans (23, 27). PBMCs from dogs were evaluated for
IFNγ production by ELISpot following stimulation with
T. cruzi lysate or PMA/ionomycin. Using 20 spot forming
units (SFU)/106 PBMCs as a cutoff for positive ELISpot
responses, 95% (19/20) of dogs seropositive by multi-
plex were also positive in the ELISpot assay while 96%
(24/25) of multiplex seronegative dogs from Argentina
or the United States were ELISpot negative (Figure 2
and Table 1). Significantly higher frequencies of IFNγ-
producing T cells in seropositive animals following PBMC
incubation with PMA/ionomycin suggested these dogs had
a higher overall active T cell compartment as compared to
seronegative dogs (Figure 2C). Little to no spontaneous
IFNγ production confirms the specificity of the ELISpot
assay to identify T. cruzi-specific T cells in the dog.
To phenotype the IFNγ producing cells, PBMCs from
a subset of ELISpot positive and negative dogs were in-
cubated with T. cruzi lysate and assessed for intracellular
IFNγ production and co-stained for expression of CD4+
or CD8+ (Figure 3A). Of the four ELISpot positive dogs,
three possessed CD4+ and CD8+ T cells producing IFNγ
in response to lysate stimulation, while one dog, dog 67,
had only CD4+ T cells producing IFNγ in response toFigure 1 Canine plasma samples tested with a multiplex bead array c
T. cruzi recombinant proteins in sera or plasma from conventional serology
T. cruzi-endemic region of Argentina and canine sera obtained from dogs i
(MFI) to the recombinant protein on a scale from 0 to 30 000 arbitrary ligh
negative and positive controls, respectively.lysate stimulation (Figure 3B-C). Taken together, these
data demonstrate that a high percentage of T. cruzi-in-
fected dogs have measurable CD4+ and CD8+ T cells re-
sponsive to T. cruzi lysate.
As T cell surface markers of activation and effector T cell
memory correlate with T. cruzi infection and disease se-
verity in humans [26,34], we next evaluated the impact of
T. cruzi infection on surface antigen expression on canine
T cells. Recent validation of T cell surface markers iden-
tifying canine T cells with activated (CTL2.58+) and
naïve or central memory (CCR7+CD62Lhi) phenotypes
has provided cell surface markers for delineating canine
T cell phenotypes (Additional file 1 and Hartley and
Tarleton, unpublished). Examining the CD8+ (Figure 4A)
and CD4+ (Figure 4B) T cell compartments, both T cell
subsets expressed measurable levels of CCR7, CD62L,
and CTL2.58. The expression and co-expression of naïve
or central memory markers CCR7 and CD62L in T cells
from healthy US control dogs were consistently higher or
significantly higher as compared to the Argentinean dogs
for both CD8+ and CD4+ T cell subsets (Figure 4C-E, G-I).
These differentiating results most likely reflect the inher-
ent environmental variation of dogs living in the United
States receiving preventative care versus dogs living in a
T. cruzi-endemic region with limited accessible veterinary
care, and thus a higher likelihood of harboring a range
of infectious agents. The antibody CTL2.58, a reagent
likely recognizing recently activated T cells and which
showed strong reactivity with both Con A stimulated
canine T cells (Additional file 1), did not appear differen-
tially expressed across any of the dog groups (Figure 4F
and J), but high CTL2.58 expression by CD8+ T cells from
a seropositive dog (Figure 4A) suggested recent T cell acti-
vation had occurred in this dog. Overall, these T cellorrelate with initial conventional serology results. Reactivity to 11
positive (seropositive) and negative (seronegative) dogs living in a
n the United States. Vertical bars represent mean fluorescence intensity
t units. Recombinant GFP and T. cruzi lysate-coated beads served as
Figure 2 Seropositive dogs have significantly higher frequencies of T. cruzi-specific PBMCs and reactive T cell compartment. A,
Interferon (IFN)-γ enzyme-linked immmunosorbent spot (ELISpot) well images of 4 × 105 PBMCs cultured with media, PMA/ionomycin (PMA/ion),
or T. cruzi lysate (TcLysate/Tc) and 1 × 104 PBMCs stimulated with PMA/ionomycin (PMA/ion (10 000)). Individual dog identification (ID) and results
of multiplex serology are denoted above wells. B-C, Numbers of IFNγ-producing PBMCs in the ELISpot assay responding to T. cruzi parasite lysate
(B) or PMA (C) adjusted to 1 × 106 or per 1 × 104 PBMCs, respectively. Each square and dot represents an individual dog, while each diamond
represents one of three US dog controls to ensure plate reproducibility. Dogs are grouped by multiplex serology negative (Sero -) or serology
positive (Sero +) from Argentina or seronegative dogs from United States. Statistical significance was determined by one-way ANOVA using Prism
v4.0c (GraphPad). Horizontal line, threshold for positive/negative response.
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status with a robust activated T. cruzi-specific T cell
response.
Discussion
T. cruzi-infected dogs are a major factor in transmission
of T. cruzi to humans [3] and are present in both rural
and urban settings [35]. Thus, identification of infected
dogs is critical for design and appropriate targeting of
T. cruzi transmission control and intervention strategies.
Towards this goal, we first tested the ability of an im-
proved serological assay utilizing T. cruzi proteins
expressed in mammalian-stage parasites [20] to detect
T. cruzi infection in dogs. Though the protein panel se-
lected for this multiplex assay was originally defined
for discriminating human sera, initial tests with a sub-
set of dog sera or plasma revealed high reactivity as well
(Figure 1). In particular, a six-protein subset was highly
discriminatory for serological status, with a minimum
two-protein reactivity of four standard deviations above
seronegative animals identifying 94% (17/18) of multiplex
serology positive dogs that were positive by conventional
serology (Table 1). Selection and screening of additional
proteins with canine plasma samples, including a broader
set of discordant dogs, would likely improve upon this
multiplex bead array assay. A single test format that
conclusively determines infection status, as opposed to
the current method of using multiple platforms and the
resulting “discordant” samples, would represent an im-
provement in diagnostics for dogs.
To our knowledge, this was the first study to evaluate
and correlate the T. cruzi-specific antibody response with
T cell phenotype and effector cytokine production in dogs.
In humans, decreases in antibody responses and in the
frequency of T. cruzi-induced IFNγ-production by T cellsand following benznidazole treatment have provided
methods to evaluate infection and treatment efficacy in
people. In the present study, our aim was to determine
if antibody responses in dogs naturally infected with
T. cruzi correlated with T. cruzi-specific T cell responses,
in efforts for ultimately identifying methods to track
canine T. cruzi infection. In contrast with human IFNγ-
ELISpot assays, where IFNγ-producing PBMCs were de-
tected in 58% of seropositive and 35% of conventional
seronegative individuals living in areas of active transmis-
sion [36], 95% of seropositive dogs and 4% of seronegative
dogs were positive in the canine IFNγ-ELISpot assay.
These data suggest dogs not only develop robust T cells
response during T. cruzi infection but the T. cruzi-specific
immune responses are much more apparent than those
present in humans. Relatively shorter terms of T. cruzi in-
fection in dogs, i.e. months to years versus decades in
humans, and the resultant decreased potential for T cell
exhaustion, as observed in human patients [34], may ex-
plain the disparity in seroreactivity and ELISpot results ob-
served between humans and dogs. Intracellular cytokine
staining allowed us to identify both CD4+ and CD8+ T
cells as responsible for IFNγ production in selected dogs
(Figure 3) at various, but low frequencies. Similar low fre-
quency of IFNγ response to T. cruzi lysate has been docu-
mented in human Chagasic patients [27]. The robust
frequency of IFNγ-producing T cells observed in seroposi-
tive dogs in the ELISpot assay provides a diagnostic
method to detect, monitor, and track canine T. cruzi infec-
tion. We would predict that, as in humans, dogs treated
with curative anti-T. cruzi drugs would exhibit predictable
changes in the frequencies of these T. cruzi-specific T cell
responses [23].
Additionally, the correlation of various T cell surface
markers with drug-induced cure has defined T cell
Figure 3 Intracellular IFNγ staining identifies T. cruzi-specific CD4+ and CD8+ T cells. A, Representative flow plots of intracellular cytokine
staining of T cells from ELISpot positive (71, 69, 43, 67) and negative canine (1,2) PBMC cultures incubated with media, PMA/ionomycin, or T. cruzi
lysate (TcLysate). Numbers indicate percentage of IFNγ-producing CD4+ or CD8+ T cells. B-C, Percentage of IFNγ-producing CD4+ (B) and CD8+
(C) T cells from individual dogs. Each bar represents a dog from Argentina (red) or United States (gray). Results of reactivity in IFNγ ELISpot assay
are denoted below each bar.
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burden during murine T. cruzi infection [30]. Similar
work in humans have correlated T cell surface marker
changes with post benznidazole treatment periods [23],
although the inability to measure these markers on bona
fide T. cruzi-specific T cells [27] provides a less dependable
marker of treatment efficacy than is possible in the mouse,
where these T cells area easily monitored using MHC tet-
ramers. Utilizing T cell-specific surface markers validated
for the dog, phenotyping of canine PBMCs provided
a method to assess hypothesized differences in global
T cell surface marker expression between seropositive and
seronegative animals. Though not statistically significant,
higher expression of CCR7 and CD62L in seronegative
versus seropositive dog T cells are consistent with thesecell surface markers identifying naïve or central memory
T cells. Seropositive dogs, on the other hand, possessed
CD4+ and CD8+ T cells expressing decreased levels of
CCR7 and CD62L. Further monitoring of these T cell sur-
face markers during the course of canine T. cruzi infection
and particularly on IFNγ-producing cells, would greatly
enhance our understanding development, maintenance,
and persistence of the canine T cell immune responses
for evaluating various intervention strategies focused on
the dog.
In addition to being important players in the trans-
mission of T. cruzi to humans [3,4,6,7], as natural hosts
that suffer clinical manifestations of Chagasic disease
[37,38], and as models for testing of anti-trypanosomal
drugs [39], canines are strong translational models for
Figure 4 T cells from seropositive dogs show signs of activation through decreased CCR7 and CD62L expression. T cells from twenty
seropositive and twenty seronegative Argentinian dogs were stained with antibodies for CCR7, CD62L, and CTL2.58, an activation marker. A-B.
Histograms of CCR7, CD62L, and CTL2.58 expression and dot plots of CCR7 and CD62L co-expression on CD8+ (A) and CD4+ (B) T cells. Numbers
indicate percentages of either CD8+ or CD4+ cells expressing CCR7 (C, G), CD62L (D, H), CCR7 and CD62L (E, I), or the activation marker, CTL2.58
(F, J). Statistical significance was determined by one-way ANOVA using Prism v4.0c (GraphPad). ** designates p < 0.001.
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characterizing the canine T. cruzi-specific immune re-
sponse is imperative for identifying infected canines in
regions of active transmission, evaluating the efficacy of
targeted canine intervention strategies, including poten-
tial vaccine strategies, and overall improving our know-
ledge of antibody and T cells responses during canine
disease. The full impact and application of serology and
T cell responses for tracking and monitoring canine T. cruziinfection and evaluating T. cruzi transmission dynamics
have yet to be determined.Additional file
Additional file 1: Induction of CTL2.58 expression on canine PBMCs
following stimulation with Con A. Canine PBMCs incubated two days
with media or ConA, harvested, and stained to identify CD4+ and CD8+
T cells and the expression of CTL2.58 (conjugated to PeCy7). Numbers
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http://www.veterinaryresearch.org/content/45/1/6indicate the percentage of CD4+ and CD8+ T cells among PBMCs (left
column) and the percentage of these subpopulations positive for the
activation molecule recognized by CTL2.58 antibody with or without Con
A stimulation (center and right columns).
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